Wagistrasse 25
Schlieren 8952
Switzerland
41 44 733 4747
https://www.kuros.ch
Settore/i:
Settore:
Impiegati a tempo pieno: 80
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Christopher T. Fair | Chief Executive Officer | 521,2k | N/D | 1970 |
Mr. Daniel Geiger | Chief Financial Officer | N/D | N/D | 1971 |
Mr. Sjoerd Musters | COO & GM of BV | N/D | N/D | 1980 |
Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D. | President of Innovation and Strategy & Executive Director | 572,6k | N/D | 1966 |
Dr. Philippe Saudan Ph.D. | Chief Development Officer | N/D | N/D | 1967 |
Mr. John Griffin | Chief Commercial Officer | N/D | N/D | N/D |
Dr. Katherine Sage D.O., FAAOS, M.S. | Senior Vice President of Medical and Clinical Affairs | N/D | N/D | N/D |
Dr. Virginia Jamieson | Consultant | N/D | N/D | 1953 |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
L'ISS Governance QualityScore di Kuros Biosciences AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.